RESearch
Welcome to our research page,
where we showcase the scientific studies and clinical trials behind our photobiomodulation (PBM) technology. Here, you’ll find detailed information about ongoing and completed research that highlights how our innovative PBM devices can support brain health and wellness. Explore published papers, trial results, and our collaborations with leading research institutions.
Dementia
Our Vielight Neuro Gamma device has been the subject of rigorous clinical studies aimed at treating dementia. Completed studies conducted by the University of California, San Francisco, in collaboration with US Veterans Affairs, and at Harvard Medical School in conjunction with Boston University School of Medicine, provide strong evidence supporting the efficacy of PBM in improving cognitive function in dementia patients.
Alzheimer’s Disease
Vielight has dedicated significant resources to understanding the impact of PBM on Alzheimer’s Disease. Our Neuro Gamma device has been evaluated in several studies, including a published review study by Vielight Inc., and clinical trials led by Unity Health in Toronto. Additionally, a large Phase 3 clinical trial at St. Michael’s Hospital involving 228 participants is currently ongoing. Prominent institutions like the University of California, San Francisco, and US Veterans Affairs are also involved in ongoing studies, further validating the potential of PBM technology in treating Alzheimer’s Disease.
Traumatic Brain Injury (TBI & CTE)
Our Neuro Gamma device has shown great promise in treating traumatic brain injury (TBI) through multiple studies. Completed trials at the Department of Neurology at the University of Utah and the VA Advanced Imaging Research Center in San Francisco have yielded positive outcomes. Moreover, research on Chronic Traumatic Encephalopathy (CTE) has been conducted by Boston University School of Medicine in collaboration with Harvard Medical School. Ongoing studies at the Boston Veterans Affairs Research Institute are exploring further applications of our technology for TBI recovery.
Parkinson’s Disease
Our Vielight Neuro Gamma and Vielight 810 [MIP] devices are being actively studied for their ability to alleviate symptoms of Parkinson’s Disease. Completed studies at the University of Sydney demonstrate encouraging results, while ongoing Phase 2 clinical trials at the University of Florida are investigating the impact of the 810 [MIP] on a larger population of 135 participants. Additionally, studies are registered at the University of Sydney and University of Brisbane to further explore the role of PBM in Parkinson’s Disease management.
PTSD & Gulf War Illness
The Vielight Neuro Alpha device has been studied in collaboration with the University of California, San Francisco, and US Veterans Affairs, showing potential for treating Post-Traumatic Stress Disorder (PTSD) and Gulf War Illness. A completed clinical study demonstrated improvements in cognitive function and psychological symptoms, making our technology a promising solution for these conditions.
Autism Spectrum Disorder (ASD)
Our Vielight Neuro Duo device has been clinically studied for its potential benefits in Autism Spectrum Disorder (ASD). The Neurodevelopment Division at the Istituto di Neuroscienze in Italy conducted a completed study, providing evidence that PBM may support cognitive and behavioral improvements in individuals with ASD.
COVID-19 Recovery
Vielight has played a pivotal role in the recovery of patients suffering from COVID-19 respiratory symptoms. Our RX Plus device recently completed a Phase 3 clinical trial with 295 participants, showing significant improvement in symptoms. This pre-print study marks a major advancement in the application of PBM for respiratory illnesses
Neuromodulation & Photobiomodulation for Creative Thinking
Vielight’s Neuromodulation technology, specifically the Gamma 40Hz and Alpha 10Hz frequencies, has been studied extensively for their benefits in brain health. Collaborations with the University of Toronto and Princeton University have demonstrated improvements in cognitive functions like creative thinking and memory. These studies pave the way for innovative treatments targeting various mental health and neurodegenerative conditions.
Antimicrobial Photodynamic Inactivation
Our Vielight Blue [MIP] device has been studied by Harvard Medical School in various applications of antimicrobial therapy. Completed studies demonstrated its effectiveness in treating infectious keratitis, Candida albicans, and other microbial conditions. This cutting-edge technology has the potential to revolutionize treatment approaches for infections through non-invasive means.
Each of these studies represents our commitment to advancing scientific understanding and delivering high-quality, effective solutions for brain health and mental wellness. We invite you to explore the research and discover how our products are transforming the field of photobiomodulation.